Inhibition of thrombin-induced platelet aggregation by creatine kinase inhibitors
AssigneeThe Regents of the University of California
InventorsVinit Mahajan, Dennis D. Cunningham, Sadashiva Pai
Life of this patent
Estimating the term…
Abstract
Methods of using creatine compounds such as creatine kinase inhibitors, and more particularly, cyclocreatine and homocyclocreatine, to inhibit thrombin-induced cytoskeletal reorganization, platelet aggregation, inflammatory processes, endothelial cell contraction and related cardiovascular and CNS disorders are described. Pharmaceutically effective amounts of creatine compounds are administered to subjects in need thereof to thereby prevent and/or treat diseases and/or pathological conditions such as thrombosis, thrombocytopenia, atherosclerosis, coronary artery disease, unstable angina pectoris, myocardial infarction, stroke, coagulopathies, and transient ischemia attacks.
Claims51
A method for inhibiting thrombin-induced platelet aggregation in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a creatine compound.
A method for inhibiting the aggregation of blood platelets in a mammal, comprising orally treating the mammal with a pharmaceutically effective amount of a creatine compound.
A method for treating a thrombotic condition in a mammal, the method comprising the administration of a therapeutic composition comprising a creatine compound to the mammal, in a dosage effective to inhibit the aggregation of platelets.
A method for promoting reperfusion of an artery or vein and inhibiting reocclusion, comprising administering to a subject in need thereof a creatine compound.
A method of preventing the formation of a thrombus in a mammal at risk of developing thrombosis, the method comprising the intravenous administration to the mammal of a therapeutic composition comprising a creatine compound in a dosage effective to inhibit the aggregation of platelets.
A method of inhibiting the aggregation of platelets on the surface of a prosthetic device comprising coating the device with a creatine compound in an amount sufficient to inhibit the aggregation of the platelets on the surface prior to exposure of the device to the platelets.
Dependencies are inferred from the claim text.